Skip to content
LiMM Therapeutics logo — LiMM is the biopharmaceutical company harnessing the molecul...

LiMM Therapeutics

LiMM is the biopharmaceutical company harnessing the molecular cross-talk between neuronal and innate lymphoid cells.

Founded 2018 France France 4 employees Grant Total: $7.00M Biotechnology, Health Care +2

General Information

Company Name LiMM Therapeutics
Founded Year 2018
Location France France
Founders / Decision Makers
Team member
Employees 4
Industries Biotechnology, Health Care, Health and Wellness +1
Funding Stage Grant
Business Model B2B, B2D
Revenue Model Licensing, Performance Based, Project Based
Social

BounceWatch is an independent company data service, not affiliated with LiMM Therapeutics. To contact LiMM Therapeutics, visit limmtx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does LiMM Therapeutics compare?

A PDF of LiMM Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting LiMM Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About LiMM Therapeutics

LiMM Therapeutics is carving a niche in the biopharmaceutical landscape through its pioneering approach to neuroimmune interactions. Founded in 2018, the company is spearheading innovation by decoding the molecular dialogues between neuronal and innate lymphoid cells in peripheral tissues—a breakthrough that is set to revolutionize the treatment of inflammatory, infectious, and metabolic diseases.

The company's groundbreaking work primarily focuses on creating NRILs (neuronal reprogrammers of innate lymphocytes), positioning them as a first-in-class therapeutic contender. LiMM Therapeutics prides itself on bridging the gap between neural sensing and immunological discoveries, thus offering novel therapeutic pathways.

Headquartered in France, the company received a substantial grant of €2.50M from the European Innovation Council in October 2021, showcasing significant confidence in its potential. With a forte in Biotechnology and Health Care, LiMM Therapeutics presents a compelling investment opportunity for those seeking to be at the forefront of medical innovation.

Business keywords: Biopharmaceutical, Neuroimmune Cross-talk, Neuronal Reprogrammers, Innate Lymphoid Cells, Therapeutics Development, Inflammatory Diseases, Infectious Diseases, Metabolic Diseases, Neural Sensing, Immunology, Molecular Cross-talk, Peripheral Tissues, First-in-Class Products, Healthcare Innovations

Services & Products

Domain Name Sales
Domain Leasing
Secure Transaction Management
Domain Transfer Facilitation

Target Customers

Entrepreneurs Startups Established Businesses Domain Investors Digital Marketing Professionals

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Grant €2.50M 1
European Innovation Council
06 Oct 2021
Seed Round Undisclosed 2
Portugal Ventures, European Innovation Council
15 Jul 2020
Seed Round €2.00M 2
Seventure Partners, PME Investimentos
12 Apr 2019
Venture Round €2.50M 2
Seventure Partners, 200M
25 Jun 2018

LiMM Therapeutics Alternatives & Competitors

View All Alternatives
LiMM Therapeutics vs

Opsona Therapeutics is a leading drug development company specialising in the human immune system....

Series C
8 employees
Biotechnology, Health Care
LiMM Therapeutics vs
Allakos Inc
Allakos Inc United States

Antibody-based therapeutics to treat various allergies and diseases

Acquired
24 employees
Biopharma, Biotechnology
LiMM Therapeutics vs
Coherus BioSciences
Coherus BioSciences United States

We are in the business of extending life for patients.

Post-IPO Equity
295 employees
Biotechnology, Health Care

FAQ About LiMM Therapeutics

LiMM is the biopharmaceutical company harnessing the molecular cross-talk between neuronal and innate lymphoid cells.
LiMM Therapeutics was founded in 2018.
LiMM Therapeutics is headquartered in France.
LiMM Therapeutics operates in Biotechnology, Health Care, Health and Wellness and Medical Devices. Its work centres on Biopharmaceutical, Neuroimmune Cross-talk, Neuronal Reprogrammers and Innate Lymphoid Cells. Its customers include Entrepreneurs, Startups and Established Businesses.
LiMM Therapeutics has a B2B and B2D business model. Its revenue comes from Licensing, Performance Based and Project Based.
LiMM Therapeutics has approximately 4 employees.
LiMM Therapeutics has completed 4 funding rounds, raising a total of $7.00M. The latest funding stage is Grant.
LiMM Therapeutics offers: Domain Name Sales, Domain Leasing, Secure Transaction Management, Domain Transfer Facilitation.
Top alternatives and competitors to LiMM Therapeutics include Opsona Therapeutics, Allakos Inc, Coherus BioSciences, CV6 Therapeutics, (NI) Ltd., OrsoBio. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
LiMM Therapeutics and Opsona Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for LiMM Therapeutics, https://bouncewatch.com/company/limm, updated 27 March 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout